🇺🇸 FDA
Pipeline program

(+)-α-DIHYDROTETRABENAZINE

ADT-2023-001

Phase 2 small_molecule active

Quick answer

(+)-α-DIHYDROTETRABENAZINE for Tardive dyskinesia is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Tardive dyskinesia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials